Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection

Rekha Khandia1, Ashok Munjal1*, Kuldeep Dhama2*, Kumaragurubaran Karthik3, Ruchi Tiwari4, Yashpal Singh Malik5, Raj Kumar Singh6 and Wanpen Chaicumpa7

1Department of Biochemistry and Genetics, Barkatullah University, Bhopal, India, 2Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India, 3Central University Laboratory, Tamil Nadu Veterinary and Animal Sciences University, Chennai, India, 4Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, Uttar Pradesh, Pratap Deen Dayal Upadhyaya Patna College, Patna, India, 5ICAR-Indian Veterinary Research Institute, Bareilly, India, 6ICAR-Indian Veterinary Research Institute, Bareilly, India, 7Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Antibody-dependent enhancement (ADE) is a phenomenon in which preexisting poorly neutralizing antibodies leads to enhanced infection. It is a serious concern with mosquito-borne flaviviruses such as Dengue virus (DENV) and Zika virus (ZIKV). *In vitro* experimental evidences have indicated the preventive, as well as a pathogenicity-enhancing role, of preexisting DENV antibodies in ZIKV infections. ADE has been confirmed in DENV but not ZIKV infections. Principally, the Fc region of the anti-DENV antibody binds with the fragment crystallizable gamma receptor (FcγR), and subsequent C1q interactions and immune effector functions are responsible for the ADE. In contrast to normal DENV infections, with ADE in DENV infections, inhibition of STAT1 phosphorylation and a reduction in IRF-1 gene expression, NOS2 levels, and RIG-1 and MDA-5 expression levels occurs. FcγRIIA is the most permissive FcγR for DENV-ADE, and under hypoxic conditions, hypoxia-inducible factor-1 alpha transcriptionally enhances expression levels of FcγRIIA, which further enhances ADE. To produce therapeutic antibodies with broad reactivity to different DENV serotypes, as well as to ZIKV, bispecific antibodies, Fc region mutants, modified Fc regions, and anti-idiotypic antibodies may be engineered. An in-depth understanding of the immunological and molecular mechanisms of DENV-ADE of ZIKV pathogenicity will be useful for the design of common and safe therapeutics and prophylactics against both viral pathogens. The present review discusses the role of DENV antibodies in modulating DENV/ZIKV pathogenicity/infection and strategies to counter ADE to protect against Zika infection.

Keywords: antibody-dependent enhancement, Dengue virus, Zika virus, pathogenesis, counteracting strategies, engineered antibodies
INTRODUCTION

Antibody-dependent enhancement (ADE) is a phenomenon in which the intensity of infection increases in the presence of pre-existing poorly neutralizing antibodies. Dengue virus (DENV) and Zika virus (ZIKV) are positive-stranded RNA viruses in the family *Flaviviridae*. Both viruses infect humans, result in similar clinical symptoms, and are transmitted mainly by mosquitoes (1, 2). The high public health concerns of ZIKV have attracted attention of worldwide researchers for designing and developing effective vaccines, drugs, therapeutics along with formulating appropriate prevention, and control strategies to counter this emerging pathogen (3, 4). ZIKV has only one serotype (5), whereas DENV comprises four recognized serotypes (DENV1–DENV4). The envelope (E) and non-structural 1 (NS1) proteins of ZIKV and DENV share sequence similarity in the range of 54.0–57.8% (6, 7). The similarity in E proteins of the four different DENV serotypes is 63%, which is slightly higher than the similarity between ZIKV and DENV (8). This sequence similarity results in a cross-reactive antibody response between ZIKV and DENV, which has been recently described (9, 10). Extensive cross-reactivity between ZIKV and DENV virus antibodies may not only create problems for antibody-based diagnosis (11) but also pose challenges because of the possibility of ADE of ZIKV infection resulting from DENV non-neutralizing antibodies as demonstrated in many *in vitro* experiments. Antibodies to DENV have been reported to interact with ZIKV, producing both protective effects (owing to cross-neutralization) (12, 13) and ADE (owing to poorly neutralizing antibodies) (14, 15). ADE of DENV infections has been observed in young children born to mothers’ who are immune to DENV. Catabolism of maternal antibodies in the child results in sub-neutralizing concentrations of antibody, which can lead to ADE (16). DENV-ADE of ZIKV infection has been well established in *in vitro* and in laboratory animal models; however, this is not the case in experiments with monkeys, in which preexisting DENV antibodies did not worsen ZIKV infection. In fact, in comparison with non-exposure, pre-exposure to DENV helped in clearing ZIKV infection more quickly in monkeys (13). Investigation of a cohort of patients, who were previously infected with DENV showed neither ADE of ZIKV infection nor significant differences in ZIKV loads (17). Reciprocally, antibodies to ZIKV have been shown to enhance DENV2 viremias in a rhesus macaque model that exhibits neutropenia, lymphocytosis, hyperglycemia, and higher reticulocyte counts, with the involvement of inflammatory mediators (18).

The phenomenon of ADE has been well documented and reproduced using both monoclonal antibodies and polyclonal sera in *in vitro* models using Fcγ receptor-expressing cells, including the cell lines K562 and U937, as well as primary human monocytes, macrophages, and dendritic cells. During ADE in THP-1 cells, type-I interferon (IFN) is suppressed, and IL-6 and IL-10 levels are increased (19, 20). ADE has been difficult to reproduce in animal models, as DENV replicates poorly in animals other than humans (approximately 1,000 times less) and severe disease outcomes such as dengue hemorrhagic fever (DHF) are not observed. IFN receptor-deficient AG129 mice, commonly used in ADE studies, display neurological symptoms and splenomegaly (21), and develop lethal vascular leakage and other symptoms similar to DHF. In non-human primates, ADE is difficult to reproduce as DHF and dengue shock syndrome (DSS) occur infrequently. However, there is little evidence for the enhancement of viremia in animals treated with below neutralizing levels of DENV antibody relative to that in controls (22). In humans also, not all studies support the existence of ADE. In a study by Libraty et al. (23), infants born to DENV3-immune mothers showed ADE in subsequent DENV3 infections, but a higher level of DENV3 ADE activity was not associated with DHF. In contrast, in another study, infants born to DENV2-immune mothers exhibited enhanced infections and DHF/DSS of less than 12 months of age (24). The present review focuses mainly on DENV-ADE and the role of DENV antibodies in possible ZIKV ADE. In addition, the role of FcγRs and different molecular events in ADE like inhibition of STAT1, IFN signaling, nitric oxide (NO) production, retinoic acid-inducible gene (RIG)-1, and melanoma differentiation-associated gene (MDA)-5 gene expression, as well as the roles of IL-10 upregulation, autophagy, and hypoxia in ADE are discussed. This review describes *in vitro* and *in vivo* experiments on ADE in various models, including mice, macaque, and humans, and the use of mAbs, polyclonal sera, or human cord blood sera in various experiments. DENV antibodies play a role in modulating immune responses, i.e., cross-protecting or causing ADE in DENV or ZIKV infection. We discuss antibody engineering, including the introduction of mutations like LALA in the Fc region, and the use of bispecific antibodies, swapping of Fc regions, and production of anti-idiotypic antibodies as some strategies that can be employed to reduce/prevent ADE by eliminating strong interactions between the Fc region of antibodies and FcγR and inhibiting antibody effector functions. These strategies may be helpful in the development of prophylactics.

THE ANTIBODY-DEPENDENT ENHANCEMENT (ADE)

The phenomenon of ADE in arbovirus infections was first described in 1964 (25). Prior to this, there were reports that preexisting non-neutralizing antibodies were responsible for enhanced infection with several human and animal viruses, including DENV (26), ZIKV (27), Ebola virus (28), HIV (29), Aleutian mink disease parvovirus (30), coxsackievirus B virus (31), equine infectious anemia virus (32), feline infectious peritonitis virus (33), simian hemorrhagic fever virus (34), caprine arthritis virus (35), porcine reproductive and respiratory syndrome virus (36), and African swine fever virus (37). Similarly, in the case of Murray Valley encephalitis (MVE) virus, higher antibody concentrations resulted in virus neutralization and reduced plaque numbers in chicken embryo (CE) cell monolayers, but with lower concentrations of antibodies, the number of plaques increased (38). Halstead et al. (39) reported that previous DENV infection predisposed humans to more severe DENV disease, and the role of ADE was hypothesized in causing severe dengue in children with secondary DENV infections. ADE was observed *in vitro*, with peripheral blood leukocytes (PBLs) from DENV-immune rhesus macaques enhancing the growth of virus. In PBLs from
non-immunized animals, DENV decay was similar to decay in a cell-free system, whereas the growth curves of DENV with PBLs from immunized animals were similar to the growth curve of other susceptible cells. This indicated the enhancement of DENV infection in PBLs in the presence of preexisting antibodies. The indirect evidence for preexisting antibodies playing a role in ADE was that PBL permissiveness to DENV was associated with the development of a humoral immune response and could be reproducibly demonstrated only in PBLs from immune donors (40). ADE was also demonstrated in rhesus monkeys, a natural DENV host, which received intravenous injections of human cord blood sera from normal or DENV-immune mothers, and higher and longer viremias were observed in animals receiving DENV-immune cord blood sera in comparison with their paired controls who received cord blood serum from non-immune donors (41).

In DENV-ADE, non-neutralizing antibodies form an immunocomplex with DENV, and this complex is internalized by Fc-receptor-bearing cells, including monocytes/macrophages and dendritic cells, culminating in an increased virus load and disease severity. A few studies have suggested that virus immune-complex-mediated suppression of intracellular antiviral responses is responsible for enhanced virus replication (19, 42), with some suggesting that increased entry of DENV through FcyR (43) or increased fusion potential of the virus (44) is behind the phenomenon of ADE.

**MOLECULAR MECHANISMS UNDERLYING DENV-ADE**

During ADE, an equal number of intracellular viral RNA copies were found in DENV and DENV-ADE-infected K562 cells (45). K562 cell is a monocytic cell line that lack type-I IFN genes; therefore, ADE in this model is independent of IFN suppression. During DENV-ADE, early suppression of NOS2 synthesis helps the virus to evade early innate immune detection. RIG-1 and MDA-5 protein expression is downregulated, whereas that of IL-10 and autophagy-related proteins such as DAK and Atg5–Atg12 is upregulated. Molecular mechanisms underlying the phenomenon of ADE have mostly been explored in *in vitro* studies on DENV. In one *in vivo* experiment, Ng et al. (46) showed increased severity of dengue disease in AG129 mice (IFN-α/β/γ receptor deficient), with DENV2-infected mice born to DENV-immune mothers dying and displaying higher levels of IL-6 and TNF-α than mice born to naive mothers. The possible mechanisms involved in ADE of DENV infections are outlined below.

(a) **Inhibition of STAT1 and interferon signaling:** An antiviral response is induced upon infection with viruses. Type-I IFNs stimulate IFN receptor subunits IFNAR1 and IFNAR2 to activate Janus kinases Jak1 and Tyk2 and signal transducers of transcription STAT1 and STAT2, which upregulate many IFN-stimulated genes (47). IFN antagonism is an essential requirement for mosquito-borne viruses to maintain high viral loads in the blood and to continue the vector–host cycle. Inhibition of IFN signaling is mediated mainly by the NS5 protein. NS5 proteins in flaviviruses exhibit functional similarities and inhibit IFN signaling through various mechanisms. In WN virus infections, NS5 targets the host protein prolylase to inhibit the expression of IFNAR1 (48); whereas in DENV infections, NS5 recruits the host ubiquitin ligase E3 component N-rexogen (UBR4) to degrade STAT2 (49). In contrast, ZIKV has been shown to bind to and reduce STAT2 levels by dose-dependent proteosomal degradation (50).

In THP-1 cells, STAT1 phosphorylation increased during DENV infection, whereas, in the case of DENV-ADE, STAT1 phosphorylation was inhibited. Similarly, IRF-1 gene expression is increased in DENV infections but reduced with DENV-ADE (51). ADE also enhances the number of fusion-positive cells and number of fusions per cell, resulting in increased internalization of virus. However, contrary to the results of other experiments, DENV2-ADE was not shown to suppress IFNs; rather, it prevented induction (44). Therefore, any increase in the amount of virus remains unnoticed initially, eventually allowing viral replication to higher titers.

(b) **Inhibition of NO expression:** NO synthesized by nitric oxide synthase 2 (NOS2), part of an innate immune response, inhibits DENV viral RNA synthesis through attenuating the RNA-dependent RNA polymerase (52). When NO levels were evaluated at different time intervals in DENV and DENV-ADE-infected cells, direct DENV infection was found to increase NOS2 levels, whereas DENV-ADE-infected cells showed decreased levels of NOS2. This result suggested initial evasion of innate immunity. In a study of 60 patients with primary DENV fever, primary DENV hemorrhagic fever, secondary DENV fever, and secondary DENV hemorrhagic fever, mean NO levels in plasma were determined. The highest viremia and lowest NO plasma levels were observed in the secondary DENV hemorrhagic fever group. NO production was not suppressed in patients with primary DENV hemorrhagic fever, suggesting a role of ADE in NO suppression (51).

(c) **Inhibition of RIG-1 and MDA-5 genes:** RIG-1 and MDA-5 genes participate in recognition of viral RNA and induce type-I IFN signaling through mitochondria antiviral protein (MAVS) (53). RIG-1 recognizes small RNAs with 5′-triphosphate caps, whereas MDA-5 recognizes long genomic RNA and replication intermediates (54). The levels of RIG-1 and MDA-5 increased in DENV-infected THP-1 cells relative to those that were uninfected; in contrast, they decreased in DENV-ADE infections. In DENV infections, expression of signaling molecules downstream of RIG-1/MDA-5 results in type-I IFN production. DENV-ADE complexes did not stimulate the expression of RIG-1/MDA-5 signaling molecules, and type-I IFN production was attenuated (19). In peripheral blood mononuclear cells (PBMCs) from patients with secondary DENV hemorrhagic fever, RIG-1, MDA-5, and IFN-β promoter stimulator (IPS)-1 were significantly suppressed in comparison with that in PBMCs of patients with DENV fever only. NF-κB is a heterodimer consisting of p65 and p50 subunits, associated with inhibitor protein
Upregulation of autophagy: autophagy contributes to cell survival during nutrient starvation, infection, and environmental and cellular stress conditions. During autophagy, cytoplasmic or cellular organelles are enclosed in double membranous vesicles called autophagosomes. Later, these autophagosomes fuse with lysosomes to form autophagolysosomes, in which cellular components are digested. Autophagy exerts both pro-viral and anti-viral effects (61). DENV infection may promote autophagy and the formation of the autophagosomes, amplifying the anti-viral effects of the autophagy. DENV replication was suppressed when autophagy was blocked with autophagy inhibitor 3-methyladenine (3-MA) (62). When infected with ZIKV, autophagy is increased in human cytotrophoblast cells (JEG-3 cell line), as evidenced by the accumulation of LC3-II in ZIKV-infected cells. The use of 3-MA, chloroquine (CQ), and Baf A1, all of which inhibit autophagy at various points, decreased ZIKV titers, whereas administration of autophagy inducers like rapamycin and Torin 1 resulted in increased ZIKV titers in trophoblasts of pregnant mice. ATG16L1 plays an essential role in autophagosome maturation by directing LC3 to autophagosomes to facilitate fusion with lysosomes. The placenta of mice hypomorphic for gene Atg16L1 (Atg16l1HM) showed an approximately 10-fold decrease in ZIKV titers in comparison with placentas from wild-type mice (63). In suckling mice infected with DENV2, the use of autophagy inducer rapamycin increased titers, whereas autophagy 3-MA decreased titers, in the brains of infected mice (64). The autophagic machinery also blocks IFN-β production (65), and a DENV non-structural protein, NS4A, uniquely upregulates autophagy. In the case of DENV-ADE, autophagy is upregulated in a PI3K-dependent manner (66).

In DENV-ADE infection, autophagy was significantly increased in pre-basophil-like KU812 cells and immature mast cell-like HMC-1 cells. NS4A and NS4B of ZIKV suppress host Akt-mTOR signaling, leading to increased autophagy for increased viral replication and impaired neurogenesis of human fetal neural stem cells (fNSCs) (67), whereas DENV NS4A alone can upregulate autophagy in epithelial cells (68). Dengue virus-ADE infection also showed an increase in the number of autophagosome vesicles, LC3 punctuation, LC3-II accumulation, and p62 degradation (68). Ubol and Halstead (69) showed that, in the presence of DENV-ADE in humans, negative regulators of RIG-1 and MDA-5 (DAK and Atg5–Atg12) were activated, disrupting RIG-1/MDA-5 signaling and limiting the type-I IFN-mediated antiviral response.

The impact of autophagy on flavivirus infections is possibly species specific. In addition, it is dependent partly on factors such as the cell line, virus strain, and autophagy inducer/inhibitors used in the study.

Role of FcγRs in ADE: FcγR generally participates in phagocytosis. Antibody-opsonized DENV enters a cell through a different pathway than non-opsonized DENV. At dilutions higher than neutralizing end points, immune complexes are formed between DENV and the antibody, which binds to the cell receptor through the Fc region to be internalized. This facilitates viral infection and a subsequent increase in virus production (70). Entry of both DENV and antibody-opsonized DENV in P388D1 cells is dynamin, actin, pH, and Rab7 dependent. DENV entry is independent of FcγR,
PI3K, and Rab5; on the other hand, infection with antibody-opsonized DENV requires all these (71). FcγR are strongly expressed by monocytes, macrophages, and dendritic cells, when these cells are infected with opsonized viruses. Through FcγRs, IgG antibodies are capable of mediating ADE infection. FcµR is rare in the phagocytes of mice and humans (72); therefore, the involvement of IgM in ADE may be negligible. However, when FcγRs are engaged in binding to immunocomplexes, instead of activating an immune response, innate immunity is suppressed by an increase in IL-10 production and Th2 bias, which eventually leads to an increase in virus output from the infected cells (73).

Secondary DENV infections result in ADE, which leads to vascular leakage and endothelial permeability (74). Pathological amounts of NS1 protein from DENV1, DENV2, DENV3, and DENV4 result in vascular leakage and endothelial dysfunction, along with the production of key inflammatory cytokines. Immunization of mice with NS1 of DENV2 protects mice from lethal DENV2 challenge or ADE. With other serotypes (DENV1, DENV3, DENV4), also NS1 immunization offered substantial protection from lethal DENV-induced vascular leakage syndrome in mice (75). Fcγ receptor-dependent (and also independent) mechanisms are involved in NS1 mAb-mediated protection, as evidenced by an experiment on congenic Fcγ receptor I- and III-deficient mice (76).

Because of its higher expression, FcγRIIA appears to be the more permissive than FcγRI for DENV-ADE. Internalization by FcγRI or FcγRIIA ligands affects the permissiveness of the complex (42). FcγRII-mediated phagocytosis has been found to be negatively regulated by FcγRIIB (77). IgG antibodies may cross the placenta and be transported through the placental blood to fetuses. In a fetus, infection is mediated by the neonatal Fc receptor (FcRn) (78). A close association between infectivity and phagocytic activity has been reported (79). FcγRIIA-mediated phagocytosis of the DENV-immune complex is initiated by lipid raft-induced receptor accumulation, which leads to the initiation of signaling cascades by the cytoplasmic domain of Ig gene family tyrosine activation motif (ITAM) molecules. ITAM molecules are phosphorylated at tyrosine residues by Src family kinases. These phosphorylated ITAM molecules recruit Syk/ZAP-70 kinases and other effectors to initiate phagocytosis (80). In WNV, a close relative of DENV, the quantity of antibodies determines this initiation process. With fewer antibodies, a single opsonized particle enters through clathrin-coated pit; a specialized membrane structure, constituting polyhedral lattice of clathrin protein to facilitate the receptor mediated endocytosis. When the antibody concentration is higher, antibody-mediated aggregates of multiple viral particles are phagocytosed (81). Similar to DENV, in visceral leishmaniasis, a protozoan disease, ADE has been demonstrated (73). When the surface of amastigotes forms an immune complex with IgG, the immune complex is ligated to FcγR, which facilitates the production of higher levels of IL-10. Leishmania disease severity is directly proportional to the levels of IL-10 in the plasma of patients (82). In DENV also, higher viremias have been associated with higher levels of IL-10 and disease severity (83). In ADE, because antibodies are non-neutralizing and present at lower levels, DENV and ZIKV are likely to enter through coated pits.

(g) Role of hypoxia in ADE: The level of oxygen plays a role in monocyte trafficking to the lymph nodes and spleen and in viral pathogenesis. Hypoxia can inhibit some viruses, such as adenovirus, influenza virus, and simian virus 40, because these viruses target O2-rich tissues; in contrast, hepatitis C virus (HCV) and Sendai virus usually reside in tissues with lower O2 levels (84–86). DENV replicates mainly in endothelial cells, fibroblasts, myeloid-derived cells, and lymphocytes (87–89). DENV is transported from the site of infection to lymph nodes by dendritic cells (90). The oxygen content of the microenvironment in lymph nodes is lower than the atmospheric oxygen level (~0.5–4.5% O2 vs. ~20% O2) (91). It is already an established phenomenon that, at a lower O2 level, immunoregulatory and inflammatory response-associated genes are overexpressed (92). At a lower O2 level, hypoxia-inducible factor-1 alpha (HIF1α) may act as a transcriptional enhancer that induces the expression of FcγRIIA. As result of FcγRIIA expression, internalization of DENV-immune complexes increases (93). In hypoxic conditions, opsonization of DENV by antibodies results in the accumulation of DENV particles. Thus, in vitro assays to determine the protective, neutralizing, or enhancing potential of antibodies against DENV or ZIKV that are conducted at higher O2 concentrations might lead to an underestimation of ADE potential in vivo (93). Evidence of the role of hypoxia in in vivo experiments is indirect (94) and has shown the upregulation of genes (PRKCB1, ARP6, PRKCD, PXN, FYN, VAMP3, DGKB, DOCK1, PTEN) involved in FcγR-mediated phagocytic signaling in mice cerebellums under hypoxic conditions.

(h) Relationship between lipid rafts and ADE: cholesterol plays a role in replication of various flaviviruses, and cholesterol metabolism is required for replication of the DENV genome (95). The major target of DENV is cells of the monocyte lineage that express FcγRs (96). Binding of IgG with lipid raft-associated FcγRs is essential for Src family kinase-mediated signaling (97), which contributes to cellular activation, cytotoxicity, and internalization of IgG-opsonized virus particles (98). For some viruses, proteins in lipid rafts act as receptors for viral entry (99). To determine the role of lipid rafts in ADE of DENV, a study was conducted with the drugs filipin, nystatin, and MjCD, which inhibit the formation of lipid rafts in U937 cells. FcγR associates with lipid rafts upon binding with IgG. These rafts were found to be an essential requirement for DENV-ADE, since inhibition of lipid raft formation reduces ADE (100). The association between the immune complexes and FcγRII formed during ADE is not stable in the absence of lipid rafts; thus, dissociation of these complexes occurs (101). Distortion of lipid rafts also prevents signaling essential for the internalization of immune complexes. Thus, drugs that inhibit lipid raft formation, such as nystatin and filipin (102), may lead to the inhibition of ADE caused by DENV (101).
Detailed molecular events during DENV infection and DENV-ADE infection are illustrated in Figure 1.

**EFFECTS OF PRE-EXISTING DENV ANTIBODIES**

As noted above, ADE is well established in DENV but still contentious in ZIKV infections. In a few experiments, DENV antibodies were found to mediate ADE in ZIKV infection, whereas in few protections from DENV antibodies have been observed. In one study, 119 mAbs were isolated from four ZIKV-infected patients; out of these, two had no history of DENV infection (ZIKV+DENV−) and two patients were determined DENV positive by serology (ZIKV+DENV+). These 119 mAbs were evaluated for DENV/ZIKV neutralization and compared side by side with mAbs isolated previously (103) from patients infected with DENV alone (DENV+ZIKV−). Out of the 119 mAbs, 41 were specific for the NS1 protein (10). The E proteins of ZIKV and DENV have three domains: EDI, involved in a structural change of the virus required for viral entry; EDII, the fusion loop; and EDIII, which is responsible for cellular binding (104). Interestingly, in the above experiment, out of 119 mAbs, mAbs against the EI and EII domains of ZIKV were found to be highly reactive to E protein of all DENV serotypes. This indicates that mAbs to the EI and EII domains are cross-reactive between ZIKV and DENV, where mAbs to EDIII are DENV or ZIKV specific. Thus, heterologous antibodies raised against EDI/II appear to be responsible for ADE (10). The notion is recently confirmed in a study into which DNA immunization to raise antibodies against E protein domain I/II was shown to enhance ZIKV infection, but the same was not observed with DNA immunization to the E protein domain III (105).

Several mAbs against both DENV and ZIKV have been isolated from immunized animal models, as well as from human convalescent serum. The panel of mAbs against both DENV and ZIKV, showing various features like cross-neutralization among flaviviruses, enhancement or inhibition of ADE in *in vitro* and *in vivo* models, and/or specificity for DENV or ZIKV, are presented in Tables 1 and 2. This information may be useful in selecting mAbs for various purposes such as identification of epitopes that do not elicit ADE-causing antibodies. mAbs that are broadly neutralizing but cause ADE, such 2A10G6, which was generated against the highly conserved flavivirus fusion loop peptide, may be engineered for safer prophylactic usage.

---

**FIGURE 1** | Events of immune response during Dengue virus (DENV) infection and DENV-antibody-dependent enhancement (ADE) infection. (A) DENV infection: (a) upon viral entry, pattern recognizing receptor (PRR) signaling activates RIG-1 and MDA-5, (b) IFN-α/β are produced, (c) NO production is upregulated, (d) phosphorylation of STAT1 is reduced, and (e) less viral progeny is produced. (B) DENV-ADE infection: (1) virus-antibody immune complex binds to FcγR and is trafficked inside the cell; (2) PRR signaling is not involved and RIG-1 and MDA-5 are suppressed; (3) IFN-α/β production is inhibited, (4) negative regulation of DAK and Atg5-Atg12; (5) disrupts the RIG-I/MDA-5 (PRRs) signaling cascade; (6) enhanced expression of p65 of NF-κB and degradation of 1 κB resulted in elevated levels of IL-6, IL-8, IL-1β, and TNF-α (pro-inflammatory cytokines); (7) IL-10 secretion enhances SOCS-3 and SOCS-1; (8) in turn attenuates STAT1 phosphorylation; (9) downregulation of IL-12 and IFN-γ; (10) NO production is suppressed; (11) autophagy is increased; and (12) more viral progeny is produced.
TABLE 1 | Various monoclonal antibodies (mAbs) developed against DENV, capable of broader neutralization; inhibition/enhancement of antibody-dependent enhancement (ADE).

| Species from which mAb is derived | Name of mAb | Domain of flavivirus involved in mAb binding | Features of mAbs | Reference |
|----------------------------------|-------------|---------------------------------------------|------------------|-----------|
| Mouse                            | 9F12        | Domain III of E glycoprotein                | Neutralize all the four DENV and WNV | Rajamanonmani et al. (106) |
|                                  | E60         | Fusion loop peptide of domain II            | Broadly neutralize other flaviviruses No binding with FcγR No activation of C1q | Crill and Chang (107) Tao and Morrison (108) |
|                                  | 4G2         | Domain II of E glycoprotein                | Broadly neutralize other flaviviruses Cause ADE of Zika in THP-1 cells Enhance ZIKV infection in K562 cell line | Charles and Christofferson (109) |
| Female BALB/c mice               | 2A10G6      | Highly conserved flavivirus fusion loop peptide (98DRXW101 motif) | Broad cross-reactivity against DENV 1–4, YFV, WNV, JEV, and TBEV | Deng et al. (110) |
| Human                            | 1C19        | Domain II of E glycoprotein                | Inhibits fusion loop (FL) antibodies and enhance ADE | Smith et al. (111) |
| DENV2-LALA mAb                   |             | Envelope Dimer Epitope I/II                | Partial inhibition of ADE | Stettler et al. (10) |
| 33.3A06                          |             | –                                           | Exhibit minimum ADE and strongly neutralize ZIKV | Priyamvada et al. (9) |
| C8                               |             | Envelope Dimer Epitope 1                   | Form and stabilize DENV envelope dimers | Rouvinski et al. (112) |
|                                  |             | Envelope Dimer Epitope 2                   |                   |           |
| C10                              |             | Envelope Dimer Epitope 1                   | High therapeutic potential (require only two doses of 10 µg to protect mice from lethal ZIKV infection) | Swanstrom et al. (113) |
|                                  |             | Virus surface E glycoprotein—at pH 6.5     | High therapeutic potential (one of the most potent mAb against ZIKV) | Zhang et al. (114) |
|                                  |             | E glycoprotein raft structure—at pH 5.0    | Prevent structural rearrangement of the E proteins—a vital step for infection. |           |
| 1.6D and D11C                    |             | FL-specific antibodies                     | Cross-reactive against ZIKV in Rhesus macaque LLC-MK2 kidney epithelial cells Unable to neutralize ZIKV | Costin et al. (115) Paul et al. (14) |

DENV ANTIBODIES IN THE ENHANCEMENT OF ZIKV

The mAb 4G2 enhance the amplitude of ZIKV infection 60-fold in culture supernatants and 248-fold in THP-1 cell pellets in comparison with their respective controls (108). The mAb 9F12, raised against the DENV2 domain III of E protein, has the ability to neutralize all four DENV serotypes, as well as WNV, even though, generally, the mAbs against this region are highly specific and do not participate in cross-neutralization (105). Adsorption and fusion analyses indicated that 9F12 plays a role during the early steps of virus entry. The single-chain variable fragment (ScFv) of 9F12 showed similar binding ability to that of the parent antibody, and thus has greater potential to be humanized and used for therapeutic and prophylactic purposes (106) (Table 1). In contrast to results of an experiment by Paul et al. (14), 1.6D and D11C were found to be non-neutralizing and to enhance ZIKV infection in FcR-bearing K562 cells by ~140-fold and ~275-fold, respectively.

Dejnirattisai et al. (15) showed that pre-incubation of anti-DENV mAbs with ZIKV caused an increase in ZIKV titers in U937 monocytes, which, without ADE, are relatively resistant to DENV/ZIKV infection. Thus, this study showed that ZIKV infection of U937 cells was enhanced by ADE.

Recently, a panel of 54 murine DENV and WNV mAbs was explored to determine their effects against ZIKV in in vitro studies. Eight out of 54 antibodies (two WNV-induced and six DENV-induced mAbs) cross-reacted with ZIKV. Out of the eight cross-reactive mAbs, two WNV-induced and one DENV-induced mAb (4G2) enhanced ZIKV infection in the human immortalized myelogenous leukemia line K562. All the enhancing antibodies belonged to isotype IgG2a (7). Similar to mAb 4G2, WNV-E18 (a WNV-elicited mAb) also bound to the DII fusion loop of the E protein, whereas WNV-E24 bound to the DIII lateral ridge of the same protein (7, 122–124). The mutated polyvalent mAb E60-hIgG1-N297Q abolished Fc-receptor binding, neutralized DENV, and prevented death in mice (125). This information regarding broadly neutralizing antibodies and their ability to cause inhibition/enhancement of ADE might be helpful in designing a vaccine that is effective against both DENV and ZIKV (Table 2).

ADE of DENV/ZIKV in the Presence of DENV Antibodies in In Vitro Models

There are numerous in vitro studies that have supported the phenomenon of ADE. Serologically naïve monkeys were inoculated with DENV serotypes 1–4, and pre- and post-infection
### Table 2 | Various monoclonal antibodies (mAbs) developed against ZIKV, capable of broader neutralization; inhibition/enhancement of antibody-dependent enhancement (ADE).

| Species from which mAb developed | Name of mAb | Domain of flavivirus involved in mAb binding | Special notes | Reference |
|----------------------------------|-------------|---------------------------------------------|--------------|-----------|
| BALB/c mice                      | D11         | NS1                                         | ZIKV specific and negligible cross-reactivity with other flaviviruses | [https://thenativeantigencompany.com/product/mouse-anti-zika-virus-ns1-antibody-d11](https://thenativeantigencompany.com/product/mouse-anti-zika-virus-ns1-antibody-d11) |
| Mice                             | ZV-67       | lateral ridge                               | Neutralize African, Asian, and American strains | [Zhao et al. (117)] |
|                                  | ZV-54       | DIII (C–C’ loop)                            | Passively transferred antibody protects mice from infection | [Zhao et al. (117)] |
|                                  | ZV-48       | DIII (ABDE sheet)                           | Poor inhibition of ZIKV infection | [Zhao et al. (117)] |
|                                  | ZV-64       | DII                                        | Support ADE of DENV | [Zhao et al. (117)] |
|                                  | ZV-2        |                                             |               | [Zhao et al. (117)] |
|                                  | ZV-13       |                                             |               | [Zhao et al. (117)] |
| Human                            | P1F12       | A unique unidentified conformational epitope | Specific for ZIKV and did not cross-react with DENV | [Magnani et al. (118)] |
|                                  | Z23 and Z3L1| To tertiary epitopes in envelope protein     | No cross-reactivity with DENV1–DENV4 | [Zhao et al. (117)] |
|                                  | ZikV-117    | DII dimer-dimer interface                   | Neutralize African, Asian, and American strains | [Zhao et al. (117)] |
|                                  | ZK2B10 and ZK7C3 | E glycoprotein                          | IC50 of 0.04 and 0.11 µg/mL, respectively, for each mAb and potently neutralizing mAb | [Yu et al. (120)] |
|                                  | ZKA190      | DIII                                        | Highly potent in ZIKV neutralization | [Stettler et al. (10)] |
|                                  | ZKA230      | Neutralizing-non-E binding                  | Potentially neutralize ZIKV | [Stettler et al. (10)] |
|                                  | ZKA64       | DIII                                        | Potentially neutralize ZIKV (IC50 values of 93 ng/mL) | [Stettler et al. (10)] |
|                                  | ZKA64-LALA  | DIII                                        | Complete blocking of ADE effect | [Stettler et al. (10)] |
|                                  | ZKA3        | Envelope Dimer Epitope I/II                 | Partial neutralization of ZIKV infectivity LALA version of antibody inhibit ADE | [Stettler et al. (10)] |
|                                  | ZKA185      | Envelope Dimer Epitope region (Neutralizing Non-Binder) | Does not react with recombinant envelope protein (E-protein) or EDIII | [Stettler et al. (10)] |
|                                  | ZIKV-116    | E, DIII, and E-FLM.                         | Neutralize diverse ZIKV strains | [Sapparapu et al. (121)] |
|                                  | ZIKV-19     | E and E-FLM                                | Weakly neutralize ZIKV infection | [Sapparapu et al. (121)] |
|                                  | ZK2B10 and ZK7C3 | E glycoprotein                          | Strongly neutralize ZIKV, DENV1, and DENV2 Therapeutic potential due to 100% protection | [Yu et al. (120)] |
|                                  | ZV67        | A strand, the BC loop, the DE loop, and the FG loop | Only ZIKV neutralizing | [Yu et al. (120)] |
|                                  | ZK8-4       | DIII/DII                                   | Poorly neutralizing, derived from a plasmablast B cell on day 4 Non-protective in mice | [Yu et al. (120)] |

Lymphocytes from these animals were infected with different DENV serotypes. In PBLs from uninfected monkeys, little virus replication occurred, whereas in PBLs from immune monkeys, there was a significant increase in DENV1, DENV2, and DENV4 titers (126). In BHK-21 cells that stably expressed FcγRIIA, ADE was demonstrated using both monoclonal antibody (mAb) 4G2, as well as DENV antibody-positive human serum (127). Similar research group has demonstrated ADE in DENV2-infected BHK cells using 6B6C, 3H12 DENV mAbs, and a virus dose of as little as 5 plaque-forming units (PFUs) (128). Anti-DENV human mAbs 1.6D and D11C directed against the fusion loop of the virus neutralize all four DENV serotypes. These mAbs cross-react with ZIKV but do not neutralize ZIKV, and they mediate ZIKV ADE in vitro in K562 cells approximately 140-fold and 275-fold for...
MAbs 1.6D and D11C, respectively (14). Preexisting immunity to DENV has been shown to enhance ZIKV titers in primary human macrophages, as well as in a human macrophage-derived cell line with an altered pro-inflammatory cytokine profile (129). ZIKV comprises one serotype with two lineages (Asian and African). Sera raised against each of these lineages are capable of neutralizing homologous or heterologous ZIKV lineages (130). Results of DENV antibody-mediated enhancement of ZIKV infection (15) and ZIKV infection-mediated enhancement of DENV infection have been documented (18, 131, 132). Human mAbs that recognize the viral envelope protein were isolated from DENV-infected patients and found to neutralize all four DENV serotypes. These mAbs resulted in DENV2 ADE in infected THP-1 cells. The F(ab′)2 fragment of these mAbs was able to neutralize all viruses in all four serotypes, similar to the parent mAb; however, no ADE activity was observed. Therefore, these mAbs are potential therapeutic candidates (133).

ADE of DENV/ZIKV in the Presence of DENV Antibodies in In Vitro Models

Although various in vitro studies have demonstrated ADE of DENV/ZIKV in the presence of DENV antibodies, the same is not true for in vivo studies. DENV antibody mediated ADE in DENV infection in vivo has been reported by several groups of researchers, but the same is not true for ZIKV. This indicates that the serotype of DENV responsible for secondary infection determines the severity of disease. In humans, immunity to one DENV serotype can cause more severe disease in secondary infection with dissimilar DENV serotypes (134). The cases of DHF/DSS, a severe form of dengue, were more prevalent in patients with primary DENV infections born to DENV-immune mothers and in those with secondary infections with DENV serotypes other than that of the first infection (135).

In addition, in cases of secondary DENV infections, the frequency of DHF/DSS was approximately 15- to 80-fold higher (34). In a study of 13 infants from Bangkok with primary DENV2 infections (age less than 12 months), all showed DHF/DSS when maternal DENV-2 neutralizing antibodies declined to an approximately 1:10 titer. Mothers of these infants each had a history of one or more DENV infections, and, as maternal IgG antibodies were catabolized and diluted, DENV2 titers were enhanced in infants (24). In an investigation involving 65 patients, those who reported prior natural DENV infections did not exhibit higher ZIKV titers upon subsequent ZIKV infection, and no ADE of ZIKV was observed in cases that were pre-exposed to DENV (17). In addition, results of a screening study of 405 individuals in Brazil and Mexico revealed that ZIKV neutralization titers were higher in individuals previously exposed to DENV1 than in those who were not previously exposed. An assessment of plasma from 168 children with acute DENV infection who attended two hospitals in Thailand indicated that disease severity was associated with higher viremias and secondary DENV infection; DENV2 was associated with more severe disease during secondary infection than in secondary infections with the other DENV serotypes (134).

Many studies have been conducted to evaluate DENV antibody-mediated ADE in ZIKV infections. In mice receiving DENV-positive convalescent serum, ZIKV titers were enhanced by more than 10-fold on day 3 and viremias were sustained for a longer time, in comparison with mice receiving control plasma or phosphate-buffered saline (136). In contrast to the results of experiments in mice, in two cohorts of rhesus macaques infected with ZIKV, those pre-infected with DENV did not exhibit more severe Zika symptoms than those that were not. In fact, the number of days of ZIKV viremia was reduced in comparison to the number in naive macaques (13). During secondary infections with DENV, CD8 + T cells target epitopes of the NS gene (137, 138). Recently, Wen et al. (139) compared the role of humoral immunity vs. CD8 + T cells in protection against ZIKV infection in DENV-immune mice by depletion and adoptive transfer of T cells. Protection was found to be mediated by CD8 + T cells. The results of this study were consistent with the results of murine studies, in which DENV-specific CD8 + T cells conferred protection against heterogenous DENV serotypes and ADE (140, 141).

Dengue virus ADE in ZIKV infections may be dependent on several factors (142). For example, the DENV serotype of a prior infection may affect disease severity as in the case of DENV infections, primary infection with DENV1 and a secondary infection with DENV2 or DENV3 can result in greater disease severity in the secondary DENV2 infection (143); the time interval between the DENV and ZIKV infections as with DENV infection, sequential infections within a span of less than 2 years can blunt the severity of disease in the secondary infection, whereas a wider time interval (2–20) years might result in a severe outcome (144); and number of previous DENV infections may affect enhancement for dengue, pre-exposure to two or more than two DENV infections can result in protection (145). It is also worth mentioning that various non-human primates and breeds of mice that are susceptible for DENV and ZIKV infection are available for research; however, DENV infection in these models does not recapitulate the features of human disease; and virus titers are consistently 1,000-fold less than titers found in humans (146). The same causes may affect the results of ADE as well. Therefore, prior to inferring any conclusions, the results must be analyzed in depth, and many species must be evaluated.

PROTECTION AGAINST ZIKV INFECTION BY DENV ANTIBODIES

Both ZIKV and DENV are flaviviruses. They show approximately 60% sequence identity, so broadly neutralizing epitopes of DENV may prevent ZIKV infection. However, type-specific mAbs such as 1F4 (DENV1 neutralizing), 2D22 (DENV2 neutralizing), 5J7 (DENV3 neutralizing), and 5H2 (DENV4 neutralizing) did not neutralize ZIKV. In addition, antibodies that are moderately cross-reactive to one DENV serotype (e.g., 4G2, 1N5, and 1M7) failed to neutralize ZIKV (147). After screening a panel of 30 cross-neutralizing human DENV mAbs, 1C19 was identified as reacting to a BC loop of the conserved domain II of the E protein. The same antibody also competes with the low-potency fusion loop (FL) antibodies, which commonly precipitates ADE (111).

The mAbs generated from memory B cells (MBCs) of ZIKV-infected patients showed various levels of binding to DENV subtypes. mAbs such as ZIKV-117 exhibited binding specificity and did not react with DENV1, DENV2, DENV3, DENV4, or...
purified WNV E protein, in contrast, ZIKV-116 bind to DENV1-, DENV2-, and DENV4. ZIKV-117, evaluated in wild-type male C57BL/6 mice with a single dose on day 1 (6.7-mg/kg dose) or day 5 (16.7-mg/kg dose) after virus inoculation, protected the animals against infection (121). Prophylaxis or post-exposure therapy is useful in treating pregnant mice and reducing virus titer in the mother, the placental and fetal tissues. Two mAbs (Z23 and Z3L1) also exhibited ZIKV-specific neutralization in vitro, with no cross-reactivity to either of the DENV serotypes.

Most of the antibodies were found to target the DENV fusion-loop epitope (FLE) of the E protein, whereas only a few targeted a site, termed as envelope dimer epitope (EDE), between two subunits of the E protein in the dimer. A structural analysis of the FLE of DENV was recently conducted by Barba-Spaeth et al. (6). Two types of EDE have been identified: EDE1, which shows improved binding capacity in the absence of glycan, and EDE2, which shows improved binding capacity in the presence of glycan (6). The mAbs to the E dimer epitope 1 (EDE1) are cross-reactive, neutralize ZIKV in cell culture, and protect against infection in a murine model. The mAbs EDE1 C8 and EDE1 C10 neutralized both a 2013 French Polynesian strain of ZIKV (H/PF/2013) and a strain from the Americas in 2015 (PRVABC59). Only two 10-µg doses of the mAb EDE1 C10 were required to protect mice from ZIKV infection (113). Hence, mAbs to EDE1 (EDE1 C10) offer protection that is superior to that of mAbs to FL (2A10G6), in terms of the quantity required to neutralize ZIKV infection and provide protection in an animal model. In addition, mAbs to EDE were weaker enhancers of ADE compared with mAbs against the fusion loop. The mAbs to EDE outperformed, showing 90% neutralization (112).

The identification of an epitope that is functionally conserved between ZIKV and DENV may help in designing a vaccine effective against both DENV and ZIKV infection (148, 149). Kam et al. (150) screened 23 human DENV mAbs for cross-reactivity with ZIKV in Vero E6 cells. The majority of the mAbs exhibited binding to ZIKV particles, with a few showing the capacity to neutralize ZIKV. The mAb SlgN-3C showed the capacity to rescue non-pregnant mice from virus-induced morbidity and mortality, whereas, in pregnant mice, it reduced viremias in placenta and fetal organs. SlgN-3C induced ADE, but when Leu-to-Ala mutations were introduced into the Fc region of this antibody, the mutated mAb (LALA-SlgN-3C) exhibited similar neutralizing efficiency as wild-type SlgN-3C but did not induce ADE. The mAb 33.3A06, which is a plasma blast-derived mAb from DENV-infected patients, potently neutralized ZIKV and exhibited minimal ADE (9).

ANTIBODY ENGINEERING TO COMBAT ADE

Because mosquitoes are the carriers for both of these viruses, concurrent ZIKV and DENV infections cannot be excluded. The Fc region of an antibody determines its half-life in serum, as well as its effector functions, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cell phagocytosis. The Fc region of an mAb may be altered to enhance its pharmacological efficacy. Depending on the purpose, the effector function may be enhanced or decreased. For example, to treat tumors, an enhanced effector function is required, whereas antibody targets present on immune cells require a reduced effector function. Binding of antibodies to FcγRs or C1q is dependent on amino-acid residues present in the hinge region and CH2 domain. Mutations that inhibit the interaction of antibody with FcγRs may be useful in preventing ADE. During ADE in DENV-infected patients, IgGs with an affinity to FcγRIIA are produced. Afucosylated antibodies were elevated in the patients suffering from severe disease associated with secondary DENV infections. Such afucosylated antibodies are non-neutralizing and activate Fc receptors. Thus, vaccine or therapeutic agents that inhibit afucosylated IgG1 can prevent ADE associated with DENV/ZIKV (151).

IgY is the primary immunoglobulin isotype in oviparous animals that is functional equivalent to mammalian IgG, but the use of avian-derived IgY has additional advantage of dissimilar genetic background and phylogenetic distance from mammals. Also, IgY is unable to bind mammalian FcγR (152) or other Fc-binding receptors, that reduce its ability to evoke an inflammatory response in humans (153). In the experiment of Fink et al. (154), goose-derived, purified anti-DENV2 IgY neutralized DENV2 both in vitro and in AG129 mouse model and prevented ADE in vitro. The goose IgY protected mice from lethal DENV challenge, by binding to the epitopes that were not previously identified (154). Thus, goose IgY is able to prevent not only DENV infection but also ADE of DENV and the same may be true for ZIKV also.

MUTATIONS IN THE Fc REGION

The Fc region of an engineered antibody must be manipulated in such a way that FcγR and C1q interactions and immune effector functions are reduced in comparison with those of native human IgG1. For this purpose, various mutations have been introduced into the CH2 domain of human IgG1, and their effects on complement-dependent toxicity and ADC have been evaluated. Inhibition of the Fc N-linked aglycosylation site (155), the LALA double mutation (Leu234Ala, together with Leu235Ala) in the Fc region of the antibody, a leucine to glutamic acid substitution at position 235 of the IgG1 Fc (156), and an N297Q substitution (125) has been observed to prevent ADE in DENV. Two variants, P329A and P329G, were assessed for their binding affinity to the receptor. P329G was less reactive with that of P329A, but both showed reduced interactions with their receptors.

Aglycosylation (N297D) or the introduction of the LALA mutation has been shown to reduce the affinity between Fc and FcγR. The ability to bind with FcγRI was found to be completely abolished in a human IgG1-P329G-LALA mutant. In a C1q binding assay, LALA, N297D, and P329G Fc mutations were silent, showing no detectable binding affinity. For human IgG1, the P329G mutation was found to have reduced binding affinity to many FcγRs, including FcγRIIa, FcγRIIIa, and FcγRIIIb (156). Engineered human antibodies with IgG1 alterations in residues at positions 233–236 in the Fc of IgG2 and at positions 327, 330, and 331 in IgG4 markedly decreased complement-dependent and antibody-dependent toxicity (157, 158). Idusoie et al. (159) reported that an alanine substitution in human IgG1 at
positions D270, K322, P329, or P331, largely hampered antibody binding with C1q and complement fixation. A broadly neutralizing human DENV mAb (D23-1G7C2-IgG1), obtained from a DENV-infected patient and developed against the envelope protein, was shown have an ADE effect.

To reduce ADE, the Fc region of D23-1G7C2-IgG1 was modified to generate antibodies of each of the IgG subclasses (IgG2–4). N297A was also introduced to reduce the affinity of these antibodies for Fcγ receptors. These changes in the Fc region resulted in reduced ADE activity in FcγRI and FcγRII-bearing THP-1 cells by the IgG2 or IgG4 subclasses. In contrast, ADE increased after it was swapped for IgG2 in FcγRII only-bearing K562 cells. This information should be exploited to obtain insight regarding antibody engineering to combat ADE against ZIKV (160). Valuable information may be obtained regarding the use of recombinant antibodies as therapeutics.

**BISPECIFIC ANTIBODIES**

A bispecific antibody (DVD-1A1D-2A10), with anti-DENV mAb 1A1D-2 (1A1D) specific to E-DIII, which inhibits attachment of DENV to a cell, and mAb 2A10, which binds to E-DII and prevents endosomal fusion of virus, show more potent neutralization than the individual antibodies. Recently, nine amino acids (positions 231–239) in the Fc domain of the DVD-1A1D-2A10 antibody were mutated at the N terminus of the Fc domain. The resulting antibodies showed a high affinity to DENV and neutralized all DENV serotypes without inducing ADE (161). Thus, similar strategies could be evaluated for the treatment of ZIKV infections.

A bispecific antibody named Fabs-in-tandem (FIT)-1, comprised on two mAbs; ZKA190 and ZKA185, which binds to DIII and DII of E protein, respectively, has been constructed. The FIT-1 has showed high *in vitro* and *in vivo* neutralization abilities along with capability to prevent viral escape mutant formation; therefore, it is having immunotherapeutic potential (162).

**ANTI-IDIOPTYPIC ANTIBODIES**

An anti-idiotypic antibody is an antibody against the antigen binding site [complementarity determining region (CDR)] of another antibody. In the case of DENV, enhancing antibodies are specific mainly to the structural pre-membrane protein (prM). Anti-idiotypic antibodies (prM-AIDs) targeting prM mAb are

![Figure 2](image_url) **FIGURE 2** | Strategies to counter Dengue virus (DENV)-antibody-dependent enhancement (ADE)/Zika virus (ZIKV). (1) Mutations in the Fc region: removal of native Fc N-linked glycosylation site and the “LALA” double mutation (Leu234Ala together with Leu235Ala) in the Fc region of antibody prevents binding to FcγRI. (2) Bispecific antibodies: bispecific antibody (DVD-1A1D-2A10) with anti-DENV monoclonal antibody (mAb) 1A1D-2 (1A1D) specific to the E-DIII, check the virus attachment to the cell, and mAb 2A10, will bind to the E-DII and further prevents the endosomal fusion of the virus. This neutralizing antibody neutralizes all the DENV serotypes without inducing ADE. Similar strategies can be employed for the ZIKV. (3) Swapping of Fc region: the Fc region of D23-1G7C2-IgG1 can be changed to generate antibodies with each of IgG subclasses (IgG2–4). The swapping of the Fc region might result in reduced ADE activity in FcγRI and FcγRII-bearing THP-1 cells in the case of IgG2 or IgG4 subclasses. (4) Anti-idiotypic antibodies: anti-idiotypic antibodies (prM-AIDAs) targeted to prM mAb largely reduces the symptoms of ADE.
generated by immunizing BALB/c mice. These polyclonal prM-AIDs greatly reduced ADE in K562 cells. In an AG6 mice model, the administration of prM-AIDs reduced ADE and decreased levels of IL-10 and ALT. This suggests that instead of using prM mAb, using prM-AIDs may be a better choice to prevent ADE during DENV infection (119). The human mAb HM14c10, obtained from a DENV patient who recovered, showed strong neutralization of DENV1 in an AG129 mouse model.

**Fab ANTIBODIES**

The Fab fragment is a part of antibody that is capable of binding with antigen, but is monovalent and lacks the Fc region. The Fab fragment of therapeutic mAb ZIKV-117 has been shown to be effective in preventing fetal infection and death in mice model. Structural analysis revealed that ZIKV-117 Fab antibodies cross-link with the monomeric units of surface E glycoprotein dimers and prevent reorganization of E protein monomers into fusogenic trimers in endosomal acidic environment (163).

The Humanyx Fab phage library was screened for the antigen HM14c10, and an E1 anti-idiotypic antibody against HM14c10 was found to potently neutralize DENV. The same could be explored to develop therapeutics (164). E1 was able to detect HM14c10- and HM14c10-like antibodies in the sera of patients who recovered from DENV infection (165), which suggested that it is a common idiotype and could be further tailored to obtain the desired results, including broader neutralization capability and diminished ADE.

The salient strategies to counter DENV/ZIKV ADE are summarized in Figure 2.

**CONCLUSION AND FUTURE PROSPECTS**

Zika virus and DENV are both vector-borne members of the *Flaviviridae* family. There is high similarity among the members of this family at the nucleotide and amino-acid levels, and this can lead to the development of cross-protective and cross-reactive antibodies. In the same geographical area, ZIKV and DENV infections may lead to generation of antibodies that might be either neutralizing or non-neutralizing. Non-neutralizing cross-reactive antibodies may lead to ADE, which is a well-known phenomenon in DENV but has not been confirmed in ZIKV infections. As most countries with confirmed ZIKV cases are also endemic for DENV, there is higher probability that ZIKV intensity may be amplified, owing to preexisting DENV cross-reactive antibodies. At present, there is evidence for the existence of in *vitro* ZIKV ADE in the presence of preexisting DENV antibodies, but in the rhesus macaque model of ADE, a reduction in viremia was observed, which indicates differences between in *vitro* and *in vivo* models. The underlying reason may be the involvement of CD8 + T-cell response in protection. These differences between *in vitro* and *in vivo* results must be understood for the successful design of a single vaccine that will provide immunity against both DENV and ZIKV. Above, we also noted that antibodies generated against EDI/II were mainly cross-reactive and might contribute to ADE of ZIKV; hence, further study is required to identify the specific region responsible for this cross-reaction. Similarly, studies should also be designed to determine whether antibodies against all serotypes of DENV cause a similar intensity of ADE in ZIKV infections.

Apart that various other factors, including the DENV serotype responsible for primary infection, the time interval between DENV and ZIKV infections and parity of DENV serotypes prior to infection with ZIKV must be taken into account to confirm ADE of ZIKV due to preexisting DENV antibodies. For this purpose, case control studies in different DENV-ZIKV endemic areas in people belonging to similar age, geographic area, ethnicity, sex, etc. Not much is known about the reciprocal response of anti-ZIKV antibodies to the enhancement of DENV infections; however, some reports have confirmed ADE of DENV in the presence of preexisting ZIKV antibodies. Studies are warranted to determine whether ADE of ZIKV can occur in the presence of antibodies to other flaviviruses. Further insights into the molecular aspects of DENV-ADE of ZIKV will assist the development of better therapeutic approaches and might also aid in the development of a pan-DENV/ZIKV vaccine. Until ADE of ZIKV infections by preexisting DENV antibodies is established, information regarding engineered antibodies and avian egg antibody will be helpful in the design of therapies with improved efficacy and safety against DENV and ZIKV infections.

**AUTHOR CONTRIBUTIONS**

All the authors substantially contributed to the conception, design, analysis and interpretation of data, checking and approving final version of manuscript, and agreed to be accountable for its contents. RK and AM initiated this review compilation. KD and YM reviewed and edited. RK designed tables. AM and KK designed the figures. KK and RT updated few critical aspects. RS reviewed virological and immunological aspects. WC reviewed the antibody engineering section. KD finally updated, edited, and overviewed.

**ACKNOWLEDGMENTS**

All the authors acknowledge and thank their respective Institutes and Universities.

**REFERENCES**

1. Singh RK, Dhama K, Malik YS, Ramakrishnan MA, Karthik K, Tiwari R, et al. Zika virus—emergence, evolution, pathology, diagnosis, and control: current global scenario and future perspectives—a comprehensive review. *Vet Q* (2016) 36(3):150–75. doi:10.1080/01652176.2016.1188333

2. Mayer SV, Tesha RB, Vasilakis N. The emergence of arthropod-borne viral diseases: a global prospective on dengue, chikungunya and Zika fevers. *Acta Trop* (2017) 166:155–63. doi:10.1016/j.actatropica.2016.11.020

3. Dhama K, Karthik K, Tiwari R, Khandia R, Munjal A, Chakraborty S, et al. Zika virus/Zika fever: a comprehensive update. *J Exp Biol Agric Sci* (2018) 6(1):1–31. doi:10.18006/2018.6(1).0.1.31
4. Singh RK, Dhamma K, Khandia R, Munjal A, Karthik K, Tiwari R, et al. Prevention and control strategies to counter Zika virus, a special focus on intervention approaches against vector mosquitoes—current updates. Front Microbiol (2018) 9:87. doi:10.3389/fmicb.2018.00087
5. Chong LD. Single serotype for Zika. Science (2016) 353(6301):787–8. doi:10.1126/science.353.6301.787-b
6. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, et al. Structural and biological potential of Zikavirus varens monocular antibodies. Virology (2017) 508:1–6. doi:10.1016/j.virol.2017.04.031
7. Williams E, Hensley SE. Characterization of Zikavirus binding and enhancement potential of a large panel of flavivirus monocular monoclonal antibodies. Virology (2017) 508:1–6. doi:10.1016/j.virol.2017.04.031
8. Xu K, Vaughan K, Weiskopf D, Grifoni A, Diamond MS, Sette A, et al. Identifying candidate targets of immune responses in Zika virus based on homology to epitopes in other flavivirus species. PLoS Curr (2016) 8. doi:10.1371/currents.outbreaks.9aa2e1f6b1f632f58a098773008c1b
9. Priyamvada L, Quicke KM, Hudson WH, Olanmony N, Sewardon T, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A (2016) 113(28):7852–7. doi:10.1073/pnas.160793111
10. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science (2016) 353(6301):823–6. doi:10.1126/science.aaf8505
11. Genicot and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis (2008) 14(8):1232–9. doi:10.3201/eid0808.080287
12. Robbiani DF, Bozzacco L, Koeffe JR, Khouri R, Olsen PC, Gazumyan A, et al. Recurrent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell (2017) 169(4):597–609. doi:10.1016/j.cell.2017.04.024
13. Pantoja P, Pérez-Guzmán EX, Rodríguez IV, White LJ, González O, Serrano C, et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun (2017) 8:15674. doi:10.1038/ncomms15674
14. Paul LM, Carlin ER, Jenkins MM, Tan AL, Carlin ER, Jenkins MM, Tan AL, et al. Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology (2016) 5(12):e117. doi:10.1038/cti.2016.72
15. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol (2016) 17(9):1102–8. doi:10.1038/ni.3515
16. Kalayanarooj S, Nimmannitya S. Clinical presentations of dengue hemorrhagic fever in infants compared to children. J Med Assoc Thai (2003) 86(5):5673–80.
17. Terzian ACB, Schanoski AS, Mata MTDO, Silva RAD, Estofelet CF, Colombo TE, et al. Viral load and cytokine response profile does not support hemorrhagic fever in dengue virus infection. J Infect Dis (2011) 204(3):489–503. doi:10.1093/infdis/jir271
18. Zompi S, Harris E. Animal models of dengue virus infection. Virus Res (2012) 14(1):62–82. doi:10.1039/v014000086
19. Halstead SB, Shiotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis (1973) 128(1):15–22. doi:10.1093/infdis/128.1.7
20. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med (2009) 6(10):e1000171. doi:10.1371/journal.pmed.1000171
21. Chaichana P, Akabayashi T, Puiprom O, Sasayama M, Sasaki T, Yamashita A, et al. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PLoS One (2014) 9(3):e92173. doi:10.1371/journal.pone.0092173
22. Castanha PMS, Nascimento EJM, Braga C, Cordeiro MT, de Carvalho OV, de Mendonça LR, et al. Dengue virus-specific antibodies enhance Brazilian Zika virus infection. J Infect Dis (2017) 215(3):758–51. doi:10.1093/infdis/jiw638
23. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol (2003) 77(13):7539–44. doi:10.1128/JVI.77.13.7539-7544.2003
24. Willey S, Aasa-Chapman MM, O’Farrell S, Pellegrino P, Williams I, Weiss RA, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology (2011) 8:16. doi:10.1186/1742-4690-8-16
25. Kanno H, Wollinburger JR, Bloom ME. Ateunit mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infection. J Virol (1993) 67(12):7017–24.
26. Sauter P, Dohm M. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of cosacksievirus B-induced diseases. Microbes Infect (2009) 11(4):443–51. doi:10.1016/j.micinf.2009.09.011
27. Raabe ML, Issel CJ, Montelaro RC. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology (1999) 259(2):416–27. doi:10.1006/viro.1999.9772
28. Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis (1981) 4:175–88. doi:10.1016/0147-9571(81)90003-5
29. Halstead SB. Immune enhancement of viral infection. Proc Allergy (1982) 31:301–64.
30. Mburuva EG, Ogubiyi PO, Gakou HS, Reddy PG. Pathogenic mechanisms of caprine arthritis-encephalitis virus. Vet Res Commun (1994) 18:483–90. doi:10.1007/BF01839425
31. Yoon KJ, Wu LL, Zimmermann JJ, Hill HT, Platt KB. Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Virus Immunol (1996) 136(9):561–3. doi:10.1089/vim.1996.9.51
32. Gomez-Villamandos JC, Carrasco L, Bautista MJ, Quezada M, Hervas J, Chacón Mde L, et al. African swine fever and classical swine fever: a review of the pathogenesis. Dtsch Tierarztl Wochenschr (2003) 110:165–9.
33. Klixs SC, Halstead SB. Role of antibodies and host cells in plaque enhancement of Murray Valley encephalitis virus. J Virol (1983) 46(2):394–404.
34. Halstead SB, Nimmannitya S, Yamarat C, Russell PK. Hemorrhagic fever in Thailand: recent knowledge regarding etiology. Jpn J Med Sci Biol (1967) 20:96–103.
35. Marchette NJ, Halstead SB, Chaw JS. Replication of dengue viruses in cultures of peripheral blood leukocytes from dengue-immune rhesus monkeys. J Infect Dis (1976) 133(3):274–82. doi:10.1093/infdis/133.3.274
36. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis (1979) 140(4):527–33. doi:10.1093/infdis/140.4.527
37. Modhiran N, Kalayanarooj S, UboI S. Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TRs signaling collapse. PLoS Negl Trop Dis (2010) 4:e924. doi:10.1371/journal. pntd.0000924
38. Taylor A, Foo SS, Bruzzzone R, Dinh LV, King NJ, Mahalingam S. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev (2015) 268(1):340–64. doi:10.1111/imr.12367
44. Filipie J, Diossa-Toro MA, Hoornweg TE, van de Pol DPJ, Urcuqui-Inchima S, Jolanda M, et al. Antibody-dependent enhancement of dengue virus infection in primary human macrophages: balancing higher fusion against antiviral responses. Sci Rep (2016) 6:22303. doi:10.1038/srep22303

45. Huang X, Yue Y, Li D, Zhao Y, Qu L, Chen J, et al. Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated type I IFN-independent signalling through upregulation of cellular autophagy. Sci Rep (2016) 6:29201. doi:10.1038/srep29201

46. Ng IKW, Zhang SL, Tan HC, Yan B, Gomez JMM, Tan WY, et al. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog (2014) 10(4):e1004031. doi:10.1371/journal.ppat.1004031

47. MacMicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol (2012) 12(5):367–82. doi:10.1038/nri3210

48. Lubick KJ, Robertson SJ, McNally KL, Freedman BA, Rasmussen AL, Taylor RT, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. J Virol (2014) 88(2):635–75. doi:10.1128/jvi.02357-07

49. Morrison J, Laurent-Rolle M, Maestre AM, Raisbaum R, Pisanelli G, Simon V, et al. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog (2013) 9(3):e1002655. doi:10.1371/journal.ppat.1002655

50. Grant A, Pronia SS, Tripathi S, Balasubramaniam V, Morin L, Sourisseau M, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe (2016) 19(6):882–90. doi:10.1016/j.chom.2016.05.009

51. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol (2007) 88(Pt 2):365–75. doi:10.1099/vir.0.82357-0

52. Takhampunya R, Padmanabhan R, Ubol S. Antiviral action of nitric oxide on dengue virus type 2 replication. J Gen Virol (2006) 87(Pt 10):3003–11. doi:10.1099/vir.0.81880-0

53. Yoneyama M, Oonoki K, Igoi M, Akabori T, Fujita T. Viral RNA detection machinery activated by dengue virus enhances virus replication. J Virol (2010) 84(21):11207–12. doi:10.1128/JVI.00316-10

54. Reikine S, Nguyen JB, Modis Y. Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front Immunol (2014) 5:342. doi:10.3389/fimmu.2014.00342

55. Lin JC, Lin SC, Chen WY, Yen YT, Lai CW, Tao MH, et al. Antibodies against West Nile virus nonstructural protein NS1 is prevented by NS1 vaccination. J Infect Dis (2014) 209(3):451–62. doi:10.1093/clinmic/nim255

56. Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. Viral RNA detection machinery activated by dengue virus enhances virus replication. J Virol (2010) 84(21):11207–12. doi:10.1128/JVI.00316-10

57. Beatty PR, Puerta-Guardo H, Kuebingke SS, Glasser DR, Hopkins K, Harris E, et al. Antibody-dependent enhancement of dengue virus infection in human pre-basophil/mast cells. PLoS One (2014) 9(10):e110655. doi:10.1371/journal.pone.0110655

58. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, et al. IL-10 levels associate with the lack of severe disease in secondary dengue 1 infection. PLoS ONE (2014) 9(10):e110655. doi:10.1371/journal.pone.0110655

59. Ye WT, Chen RF, Liu JW, Shao MF, Yang KD. Implications of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol (2007) 88(Pt 2):365–75. doi:10.1099/vir.0.82357-0

60. Reikine S, Nguyen JB, Modis Y. Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front Immunol (2014) 5:342. doi:10.3389/fimmu.2014.00342

61. Lin JC, Lin SC, Chen WY, Yen YT, Lai CW, Tao MH, et al. Dengue virus protease interaction with NF-κB inhibitor α/β results in endothelial cell apoptosis and hemorrhage development. J Immunol (2014) 193(3):1258–67. doi:10.4049/jimmunol.1302657

62. Nguyen TL, Lei HY, Liu MT, Wang JR, Chen SH, Jiang-Shieh YF, et al. Autophagic machinery activated by dengue virus enhances virus replication. Virology (2008) 374(2):240–8. doi:10.1016/j.virol.2008.02.016

63. Cao B, Parnell LA, Diamond MS, Mysorekar IU. Inhibition of autophagy limits viral transmission of Zika virus in pregnant mice. J Exp Med (2017) 214(8):2303–13. doi:10.1084/jem.20170957
84. Riedinger HJ, van Betteraey M, Probst H. Hypoxia blocks in vivo initiation of simian virus 40 replication at a stage preceding origin unwinding. J Virol (1999) 73:2243–52.
85. Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther (2005) 12:911–7. doi:10.1038/sj.gene.6320459.
86. Vassilikos N, Kalliampaku KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, et al. Low oxygen tension enhances hepatitis C virus replication. J Virol (2013) 87:2935–48. doi:10.1128/JVI.02534-12.
87. Halstead SB, O’Rourke EL, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes in vivo by fluorescence in vivo. J Exp Med (1977) 146(1):218–29. doi:10.1084/jem.146.1.218.
88. Noisakran S, Onlamoon N, Songrakphon F, Hsiao HM, Choikehuabulkitt K, Perig GC. Cells in dengue virus infection in vivo. Adv Viro (2010) 2010:164878. doi:10.1155/2010/164878.
89. Aye KS, Charrngkaew K, Win N, Wai KZ, Punyadee N, et al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol (2014) 45:1221–33. doi:10.1016/j.ajpath.2014.01.022.
90. Prestwood TR, May MM, Plummer EM, Morar MM, Yauch LE, Shresta S. Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice. J Virol (2012) 86:12318–47. doi:10.1128/JVI.00375-12.
91. Carreani A, HafnyRahbi BE, Matejuk A, Grillen C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med (2011) 15:2393–5. doi:10.1111/j.1582-4934.2011.01258.x.
92. Bosco MC, Pierobon B, Blengio F, Raggi F, Vanni C, Gattorno M, et al. Hypoxia modulates the gene expression profile of immunoreceptorreceptors in human mDCs: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood (2011) 117:2625–39. doi:10.1182/blood-2010-06-292136.
93. Gan ES, Cheong WF, Chan KR, Ong EZ, Chan JY, et al. Hypoxia enhances antibody-dependent dengue virus infection. EMBO J (2017) 36(10):1348–63. doi:10.15252/embj.201695642.
94. Xu H, Lu A, Sharp FR. Regional genome transcriptional response of adult mouse brain to hypoxia. BMC Genomics (2011) 12:499. doi:10.1186/1471-2164-12-499.
95. Rothwell C, LeBreton A, Ng CY, Lim JYH, Liu W, Vasudevan S, et al. Low oxygen tension enhances hepatitis C virus infection. J Virol (2011) 85(24):12149–59. doi:10.1128/JVI.01258.x.
96. Kyle JL, Beatty PR, Harris E. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Virol (2017) 91:394–403. doi:10.1128/JSI.M12540-0.
97. Unkeless JC, Shen Z, Lin CW, DeBeus E. Function of human Fc gamma receptor pathways during active and passive immunization. J Exp Med (1977) 146(1):218–29. doi:10.1084/jem.146.1.218.
98. Bournazos S, Ravetch JV. Fc receptor pathways during active and passive immunization. J Immunol (1989) 143(8):2595–601.
99. Suzuki T, Suzuki Y. Virus infection and lipid rafts. Adv Virol (2010) 2010:164878. doi:10.1155/2010/164878.
100. Slon Campos JL, Poggiamellia M, Morsen S, Massenta M, Rana J, Arnoldi F, et al. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. PLoS One (2017) 12(7):e0181734. doi:10.1371/journal.pone.0181734.
101. Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shogat SC, Sukupolvi-Petty S, et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol (2009) 90(Pt 4):799–809. doi:10.1099/ viz.0.006874-0.
102. Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, et al. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One (2011) 6(1):e16059. doi:10.1371/journal.pone.0016659.
103. Smith SA, de Alwis AR, Kose N, Harris E, Bhatta KD, Kahle KM, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio (2013) 4:e00873–813. doi:10.1128/mBio.00873-13.
104. Rouvinis A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaaney MC, Kikutti CM, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature (2015) 520(7545):109–13. doi:10.1038/nature14130.
105. Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2013) 87(1):52–66. doi:10.1128/JVI.02273-12.
106. Available from: https://thenativeantigencompany.com/product/mouse-an- ti-zika-virus-nl-antibody-d11/ (accessed December 26, 2017).
107. Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, et al. Structural basis of Zika virus-specific antibody protection. Cell (2016) 164(4):1016–27. doi:10.1016/j.cell.2016.07.020.
108. Magnani DM, Silveira CGT, Rosen BC, Ricciardi MJ, Pedreño-Lopez N, Gutman MJ, et al. A human inferred germline antibody binds to an immuno- nodominant epitope and neutralizes Zika virus. J Virol (2018) 92(1):254–65. doi:10.1128/JVI.00565-18.
109. Wang M, Yang F, Huang D, Huang Y, Zhang X, Wang C, et al. Anti-idiotypic antibodies specific to prM monomabodyt prevenab antibody dependent enhancement of dengue virus infection. Front Cell Infect Microbiol (2017) 7:157. doi:10.3389/fcimb.2017.00157.
110. Yu L, Wang R, Gao F, Li M, Liu J, Wang J, et al. Delineating antibody recognition against Zika virus during natural infection. JCI Insight (2017) 2(12):e93042. doi:10.1172/jci.insight.93042.
111. Sappapragu G, Fernandez E, Kose N, Cao B, Fox JM, Bombardi RG, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature (2016) 540:443–7. doi:10.1038/nature20564.
112. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 11:522–30. doi:10.1038/ nm1240.
113. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J Virol (2008) 80:12149–59. doi:10.1128/JVI.01732-06.
Khandia et al. Modulation of DENV/ZIKV Pathogenicity by ADE

124. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 80(8):4053-60. doi:10.1128/JVI.00800-06

125. Moi ML, Lim CK, Cardenas J, Hall A, Perez OG, Cardenas L, et al. A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement. J Gen Virol (2017) 98(7):1702–12. doi:10.1099/ jgv.0.008833

126. Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith AR, Goo L, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep (2016) 16:1485–91. doi:10.1016/j.celrep.2016.07.049

127. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG-Fc receptor interactions illuminated by crystal structures. Immunol Lett (2016) 163(2):205–9.

128. Sasaki T, Setthapramotebj C, Kurosuaj T, Nishimuraaj M, Asaiaj A, Mahalingam S, Teixeira MM, Halstead SB. Zika enhancement: a reality check. Arch Virol (2014) 159(1):103–16. doi:10.1007/s00705-013-1787-3

129. Mahalingam S, Teixeira MM, Halstead SB. Zika enhancement: a reality check. Lancet Infect Dis (2017) 17(8):686–8. doi:10.1016/S1473-3099(17)3040-7

130. Sasaki T, Sethapramotebj C, Kurosuaj T, Nishimuraaj M, Asaiaj A, Omokokoaj MD, et al. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Antiviral Res (2013) 98(3):423–31. doi:10.1016/j.antiviral.2013.03.018

131. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Momin M, et al. Dengue virus viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 181(1):2–9. doi:10.1086/315215

132. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, et al. Advances in developing therapies to combat Zika virus: current knowledge and future perspectives. Front Microbiol (2017) 8:Article 1469. doi:10.3389/fmicb.2017.01469

133. Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcγR: current models. Immunol Lett (2002) 82(1–2):57–65. doi:10.1016/S0165-2478(02)00119-6

134. Zellweger RL, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2000) 160(8):4178–84. doi:10.1128/ jimmunol.164.8.4178

135. Zellweger RL, Eddy WE, Tang WW, Miller R, Shresta S. CD8+ T cells can mediate short-term protection against heterotypic dengue virus infection in mice. J Virol (2015) 89:6494–505. doi:10.1128/JVI.00336-15

136. Girgis S, Zellweger RL, Burton DR. A bispecific antibody that recognizes both FcγRIIa and FcγRIIb and completely abolishes immune effector functions. Protein Eng Des Sel (2016) 29(10):457–66. doi:10.1093/protein/gzw040

137. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the C1q binding site on rituxan, a chimeric antibody receptor I binding and monocyte triggering activities. Eur J Immunol (1999) 29(8):2613–20. doi:10.1002/ ejj.1030990810

138. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking FcγR receptor I binding and monocyte triggering activities. Eur J Immunol (1999) 29(8):2613–20. doi:10.1002/ ejj.1030990810

139. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournaos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. Science (2017) 355(6332):395–8. doi:10.1126/science.aai8128

140. Larsson A, Bälow RM, Lindahl TL, Forsberg PO. Chicken antibodies: taking advantage of evolution—a review. Poult Sci (1993) 72(10):1807–12. doi:10.3382/pou.0721807

141. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournaos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. Science (2017) 355(6332):395–8. doi:10.1126/science.aai8128

142. Khandia R, Dhama K, Sachan S, Karthik K, Tiwari R, et al. Antibody with an engineered Fc region as a therapeutic agent against dengue virus. J Immunol (2013) 180(9):5747–54. doi:10.4049/jimmunol.2012000571

143. Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg (2007) 77(5):910–3.

144. Shresta S, Khandia R, Dhaa R, Pant S, Kouris G, Vázquez S, Halstead SB. Enhanced antibody-dependent enhancement of dengue virus replication. Nat New Biol (2010) 462(7285):261–4. doi:10.1038/nature08409

145. Shi X, Deng Y, Wang H, Ji G, Tan W, Jiang T, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun (2015) 6:6384. doi:10.1038/ ncomms7341

146. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournaos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. Science (2017) 355(6332):395–8. doi:10.1126/science.aai8128

147. Jefferis R, Lund J. Interaction sites on human IgG-Fc for FgammRa: current models. Immunol Lett (2002) 82(1–2):57–65. doi:10.1016/ S0165-2478(02)00119-6

148. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma R1, Fc gamma RII, FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2001) 276(9):6591–604. doi:10.1074/jbc.M009483200

149. Shi X, Deng Y, Wang H, Ji G, Tan W, Jiang T, et al. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous cross antigen-induced antibody-dependent enhancement of dengue disease severity. J Virol (2014) 88(21):11857–66. doi:10.1128/ jvi.00577-14

150. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournaos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. Science (2017) 355(6332):395–8. doi:10.1126/science.aai8128

151. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournaos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. Science (2017) 355(6332):395–8. doi:10.1126/science.aai8128

152. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournaos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcRIIIA binding determine disease severity. Science (2017) 355(6332):395–8. doi:10.1126/science.aai8128
163. Hasan SS, Miller A, Sapparapu G, Fernandez E, Klose T, Long F, et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. *Nat Commun* (2017) 8:14722. doi:10.1038/ncomms14722

164. Lim SY, Chan CE, Lisowska MM, Hanson BJ, MacAry PA. The molecular engineering of an anti-idiotypic antibody for pharmacokinetic analysis of a fully human anti-infective. *PLoS One* (2015) 10(12):e0145381. doi:10.1371/journal.pone.0145381

165. Wong YH, Goh BC, Lim SY, Teo EW, Lim APC, Dedon PC, et al. Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype Fab complex. *J Virol* (2017). doi:10.1128/JVI.00406-17

**Conflict of Interest Statement:** All authors declare that there exist no commercial or financial relationships that could in any way lead to a potential conflict of interest.

The reviewer EV, LL and handling Editor declared their shared affiliation.

Copyright © 2018 Khandia, Munjal, Dhama, Karthik, Tiwari, Malik, Singh and Chaicumpa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.